Status:
COMPLETED
Antiretroviral Therapy and Extreme Weight
Lead Sponsor:
Hopital Lariboisière
Conditions:
HIV Infection
Eligibility:
All Genders
18-80 years
Brief Summary
The concentration of the third agent in antiretroviral therapy \[Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI), or boosted Protease inhibitor (PI) \] is different according to the body weight...
Detailed Description
Our primary endpoint is the individual trough concentrations of interest at steady state for NNRTI or boosted PI; Principal outcome measure: comparison of the concentrations between patients \<25kg/m2...
Eligibility Criteria
Inclusion
- Patients with HIV+ receiving one of the following third agent their HAART: efavirenz, atazanavir , or darunavir
- Patients aged \> 18 years old.
- Patient giving its well-informed and free consent. Patient giving its well-informed and free consent.
- Patients living in France during the study.
Exclusion
- Treatment with rifampin/rifabutin
Key Trial Info
Start Date :
September 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT01805427
Start Date
September 1 2012
End Date
November 1 2013
Last Update
December 6 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Lariboisiere
Paris, Île-de-France Region, France, 75010